Protalix Biotherapeutics Inc (United States) is listed on the Nasdaq and has a market capitalization of $219.56 million, with shareholders equity totaling $71.40 million.
The company employs approximately 226 people and operates in the Others sector, within the Others industry.
Over the past 12 months, Protalix Biotherapeutics Inc reported $80.62 million in revenue, generating net income of $18.95 million.
Key financial metrics include a P/E ratio of 11.59, a price-to-book (P/B) ratio of 3.07, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker PLX.